PPCB (NASDAQ:PPCB – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, FiscalAI reports.
PPCB Trading Up 3.3%
Shares of PPCB stock traded up $0.01 during trading hours on Tuesday, hitting $0.22. The stock had a trading volume of 558,326 shares, compared to its average volume of 2,201,205. The stock has a market capitalization of $3.32 million, a price-to-earnings ratio of 0.00 and a beta of 3.66. PPCB has a one year low of $0.16 and a one year high of $11.00.
Wall Street Analyst Weigh In
Separately, Weiss Ratings started coverage on shares of PPCB in a research report on Wednesday, January 14th. They set a “sell (e-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.
PPCB Company Profile
Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.
Featured Stories
- Five stocks we like better than PPCB
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for PPCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPCB and related companies with MarketBeat.com's FREE daily email newsletter.
